CD8‐positive peripheral T cell lymphoma in a patient following long‐term nivolumab for advanced lung adenocarcinoma: A case report
Abstract A 54‐year‐old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and peripheral atypical lymphocytosis appeared after 33 cycles of second‐line treatment with nivolumab, an...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-06-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.13966 |
id |
doaj-606fc10c954446a4bc8ec157446e76ff |
---|---|
record_format |
Article |
spelling |
doaj-606fc10c954446a4bc8ec157446e76ff2021-06-01T23:59:09ZengWileyThoracic Cancer1759-77061759-77142021-06-0112111765176910.1111/1759-7714.13966CD8‐positive peripheral T cell lymphoma in a patient following long‐term nivolumab for advanced lung adenocarcinoma: A case reportKeigo Koda0Mikio Toyoshima1Shusuke Yazawa2Atsuki Fukada3Haruhiko Sugimura4Takafumi Suda5Department of Respiratory Medicine Hamamatsu Rosai Hospital Hamamatsu JapanDepartment of Respiratory Medicine Hamamatsu Rosai Hospital Hamamatsu JapanDepartment of Respiratory Medicine Hamamatsu Rosai Hospital Hamamatsu JapanDepartment of Respiratory Medicine Hamamatsu Rosai Hospital Hamamatsu JapanDepartment of Tumor Pathology Hamamatsu University School of Medicine Hamamatsu JapanSecond Department of Internal Medicine Hamamatsu University School of Medicine Hamamatsu JapanAbstract A 54‐year‐old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and peripheral atypical lymphocytosis appeared after 33 cycles of second‐line treatment with nivolumab, and a specimen obtained by left inguinal lymph node biopsy showed peripheral T cell lymphoma (PTCL), not otherwise specified. Lymphoma cells expressed CD3+, CD8+, and CD56+, but not CD4+ or PD‐1. Despite systemic chemotherapy with cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisolone, the patient died of PTCL 864 days after the initial visit. The possible relationship between treatment with immune checkpoint inhibitors (ICIs) and PTCL development is discussed here.https://doi.org/10.1111/1759-7714.13966immune checkpoint inhibitornivolumablung cancerT cell lymphoma |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Keigo Koda Mikio Toyoshima Shusuke Yazawa Atsuki Fukada Haruhiko Sugimura Takafumi Suda |
spellingShingle |
Keigo Koda Mikio Toyoshima Shusuke Yazawa Atsuki Fukada Haruhiko Sugimura Takafumi Suda CD8‐positive peripheral T cell lymphoma in a patient following long‐term nivolumab for advanced lung adenocarcinoma: A case report Thoracic Cancer immune checkpoint inhibitor nivolumab lung cancer T cell lymphoma |
author_facet |
Keigo Koda Mikio Toyoshima Shusuke Yazawa Atsuki Fukada Haruhiko Sugimura Takafumi Suda |
author_sort |
Keigo Koda |
title |
CD8‐positive peripheral T cell lymphoma in a patient following long‐term nivolumab for advanced lung adenocarcinoma: A case report |
title_short |
CD8‐positive peripheral T cell lymphoma in a patient following long‐term nivolumab for advanced lung adenocarcinoma: A case report |
title_full |
CD8‐positive peripheral T cell lymphoma in a patient following long‐term nivolumab for advanced lung adenocarcinoma: A case report |
title_fullStr |
CD8‐positive peripheral T cell lymphoma in a patient following long‐term nivolumab for advanced lung adenocarcinoma: A case report |
title_full_unstemmed |
CD8‐positive peripheral T cell lymphoma in a patient following long‐term nivolumab for advanced lung adenocarcinoma: A case report |
title_sort |
cd8‐positive peripheral t cell lymphoma in a patient following long‐term nivolumab for advanced lung adenocarcinoma: a case report |
publisher |
Wiley |
series |
Thoracic Cancer |
issn |
1759-7706 1759-7714 |
publishDate |
2021-06-01 |
description |
Abstract A 54‐year‐old male smoker presented with hemoptysis. Advanced lung adenocarcinoma, cT1cN3M1b, stage IVB, was diagnosed. Enlargement of multiple intraperitoneal and inguinal lymph nodes and peripheral atypical lymphocytosis appeared after 33 cycles of second‐line treatment with nivolumab, and a specimen obtained by left inguinal lymph node biopsy showed peripheral T cell lymphoma (PTCL), not otherwise specified. Lymphoma cells expressed CD3+, CD8+, and CD56+, but not CD4+ or PD‐1. Despite systemic chemotherapy with cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisolone, the patient died of PTCL 864 days after the initial visit. The possible relationship between treatment with immune checkpoint inhibitors (ICIs) and PTCL development is discussed here. |
topic |
immune checkpoint inhibitor nivolumab lung cancer T cell lymphoma |
url |
https://doi.org/10.1111/1759-7714.13966 |
work_keys_str_mv |
AT keigokoda cd8positiveperipheraltcelllymphomainapatientfollowinglongtermnivolumabforadvancedlungadenocarcinomaacasereport AT mikiotoyoshima cd8positiveperipheraltcelllymphomainapatientfollowinglongtermnivolumabforadvancedlungadenocarcinomaacasereport AT shusukeyazawa cd8positiveperipheraltcelllymphomainapatientfollowinglongtermnivolumabforadvancedlungadenocarcinomaacasereport AT atsukifukada cd8positiveperipheraltcelllymphomainapatientfollowinglongtermnivolumabforadvancedlungadenocarcinomaacasereport AT haruhikosugimura cd8positiveperipheraltcelllymphomainapatientfollowinglongtermnivolumabforadvancedlungadenocarcinomaacasereport AT takafumisuda cd8positiveperipheraltcelllymphomainapatientfollowinglongtermnivolumabforadvancedlungadenocarcinomaacasereport |
_version_ |
1721410118621331456 |